网络药理学和生化实验揭示了用于治疗糖尿病性视网膜病的huperzine A的抗凋亡机制。
摘要来源：
br j ophthalmol。 2024 Jun 20; 108（7）：989-998。 EPUB 2024 6月20日。PMID： 37339867“> 37339867 Guannan Bai, Wei Wu, Houfa Yin, Lidan Hu, Xiangjun Chen
Article Affiliation:Ying Zhang
Abstract:BACKGROUND/AIMS: Diabetic retinopathy is the most common eye disease that causes blindness in the working population.神经变性是糖尿病性视网膜病的早期迹象，但尚未批准延迟或逆转视网膜神经变性的药物。 huperzine A是一种从Huperzia Serrata分离的天然生物碱，在治疗神经退行性疾病中显示神经保护作用和抗凋亡作用。我们的study aims to investigate the effect of huperzine A in preventing retinal neurodegeneration of diabetic retinopathy and its possible mechanism.
METHODS: Diabetic retinopathy model was induced by streptozotocin. H＆E染色，光学相干断层扫描，免疫荧光染色和血管生成因子用于确定视网膜病理损伤的程度。 The possible molecular mechanism was unrevealed by network pharmacology analysis and further validated by biochemical experiments.
RESULTS: In our study, we demonstrated that huperzine A has a protective effect on the diabetes retina in a diabetic rat model.基于网络药理学分析和生化研究，Huperzine A可以通过关键靶标HSP27和与凋亡相关的途径治疗糖尿病性视网膜病变。 Huperzine A可能会调节Hsp27的磷酸化并激活抗凋亡符号Alling途径。
结论： 我们的发现表明，huperzine a可能是预防糖尿病性视网膜病的潜在治疗药物。这是首次将网络药理学分析与生化研究结合起来，探讨了Huperzine A预防糖尿病性视网膜病的机制。